

OPAL - Cross-sectional study assessing the prevalence of co-addictions in subjects receiving opioid substitution treatment: determination of the clinical and pharmacological profile

Head :Grall-Bronnec Marie, Addiction department of the CHU de Nantes / UIC 18 Clinical Investigation Unit:
Behavioural addictions and complex mood disorders / EA 4275 SPHERE

Last update : 02/17/2020 | Version : 1 | ID : 73282

General

Identification

Detailed name Cross-sectional study assessing the prevalence of co-addictions in subjects receiving opioid substitution treatment: determination of the clinical and pharmacological profile

Sign or acronym OPAL

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL: authorisation No. 913237 / CCTIRS: No. 13.223

General Aspects

Medical area Biology
Psychology and psychiatry

Health determinants Addictions
Genetic

Keywords Opioid dependence, opioid substitution treatment, psychoactive substance, pharmacokinetics, pharmacogenetics, polymorphism, cytochrome P450 2D6, addictions, pathological gambling

Scientific investigator(s) (Contact)

Name of the director Grall-Bronnec

Surname Marie

Address IFAC
Batiment Louis Philippe
Hopital St Jacques
85 rue St Jacques
44 093 Nantes cedex 01

Phone + 33 (0)2 40 84 61 16

| | |
|--------------|--|
| Email | marie.bronnec@chu-nantes.fr |
| Unit | Addiction department of the CHU de Nantes / UIC 18 Clinical Investigation Unit: Behavioural addictions and complex mood disorders / EA 4275 SPHERE |
| Organization | Chu de Nantes |

Collaborations

Participation in projects, networks and consortia Yes

Details Multicentric study in collaboration with the CHU de Brest, CHU d'Angers, CH de Morlaix, CH G. Régnier de Rennes, CSAPA "Le Triangle" (Nantes), "La métairie" (La Roche S / Yon) And "La Rose des Vents" (St Nazaire), the SMPR in Nantes and the Addictions Network of the Nantes Region (RTRN)

Funding

Funding status Public

Details Interministerial Mission for Combating Drugs and Addictive Behaviours (MILDECA)

Governance of the database

Sponsor(s) or organisation(s) responsible Chu de Nantes

Organisation status Public

Presence of scientific or steering committees No

Additional contact

Main features

Type of database

Type of database Study databases

Study databases (details) Not-repeated cross-sectional studies (except case control studies)

Database recruitment is carried out by an intermediary A selection of health institutions and services

| | |
|--|---|
| Database recruitment is made on the basis of: | Medication(s) taken |
| Database recruitment is carried out as part of an interventional study | No |
| Additional information regarding sample selection. | The study will focus on patients with a prescribed OST due to opioid dependence, whether the OST is methadone, buprenorphine (+/- naloxone) or a morphine-based drug. Recruitment is multicentric (10 centres in the western region participated in this study) |

Database objective

| | |
|--------------------|--|
| Main objective | assess the current prevalence of addictive comorbidities in opioid-dependent subjects who have been receiving opioid substitution therapy (OST) for at least 6 months. |
| Inclusion criteria | <p>Adult</p> <p>Treatment with methadone or buprenorphine (+/- naloxone) or morphine as a substitute, prescribed for opioid dependence</p> <p>OST established for at least 6 months</p> <p>Incarceration of less than one month if monitored by a Regional Medical and Psychological Service (SMPR) in prison</p> <p>Good understanding of French, knowing how to read and write it.</p> |

Population type

| | |
|------------------------------|---|
| Age | <p>Adulthood (19 to 24 years)</p> <p>Adulthood (25 to 44 years)</p> <p>Adulthood (45 to 64 years)</p> <p>Elderly (65 to 79 years)</p> |
| Population covered | Sick population |
| Pathology | V - Mental and behavioural disorders |
| Gender | <p>Male</p> <p>Woman</p> |
| Geography area | National |
| Detail of the geography area | Nantes, Brest, Morlaix, Angers, Rennes, St Nazaire |

Data collection

Dates

| | |
|--|---------|
| Date of first collection (YYYY or MM/YYYY) | 11/2013 |
|--|---------|

| | |
|---|------|
| Date of last collection (YYYY or MM/YYYY) | 2016 |
|---|------|

Size of the database

| | |
|--|-------------------|
| Size of the database (number of individuals) | < 500 individuals |
|--|-------------------|

| | |
|--------------------------------------|-----|
| Details of the number of individuals | 263 |
|--------------------------------------|-----|

Data

| | |
|-------------------|---------------------------|
| Database activity | Data collection completed |
|-------------------|---------------------------|

| | |
|------------------------|-----------------------------------|
| Type of data collected | Clinical data Declarative data |
|------------------------|-----------------------------------|

| | |
|------------------------|--------------------------|
| Clinical data (detail) | Direct physical measures |
|------------------------|--------------------------|

| | |
|---------------------------|--|
| Declarative data (detail) | Paper self-questionnaire Face to face interview |
|---------------------------|--|

| | |
|-----------------------|-----|
| Presence of a biobank | Yes |
|-----------------------|-----|

| | |
|---------------------|-------------|
| Contents of biobank | Whole blood |
|---------------------|-------------|

| | |
|---------------------------|------------------------|
| Health parameters studied | Health event/morbidity |
|---------------------------|------------------------|

Procedures

| | |
|------------------------|--|
| Data collection method | collection of data in consultation by the physician and/or nurse |
|------------------------|--|

| | |
|---------------------------|--|
| Quality procedure(s) used | Verification of data by a Clinical Study Technician and the consistency of data by the data cell when entering it into the computer database |
|---------------------------|--|

| | |
|------------------------|----|
| Participant monitoring | No |
|------------------------|----|

| | |
|--------------------|--|
| Followed pathology | |
|--------------------|--|

| | |
|---------------------------------|----|
| Links to administrative sources | No |
|---------------------------------|----|

Promotion and access

Promotion

Access

Terms of data access (charter for data provision, format of data, availability delay)

Contact the scientist in charge.

Access to aggregated data

Access on specific project only

Access to individual data

Access on specific project only